Iovance Biotherapeutics: And 9.01 Of The Current Report On Form 8k, Originally Filed On January 23, 2023 (the Original 8k ) Of Iovance Biotherapeutics, Inc. (the Company ). The Original 8k Reported (x) The Entry Of The Company And Its Newly Formed, Wholly Owned Subsidiary, Iovance Biotherapeutics Uk Ltd ( Purchaser ) Into An Option Agreement (the Agreement ) With Clinigen Holdings Limited, Clinigen Healthcare Limited, And Clinigen, Inc. And (y) That The Company Has Agreed To Nonbinding Terms Related To A Proposed Secured Line Of Credit Of Up To $100.0 Million From Quogue Capital Llc (the Line Of Credit ). This Current Report On Form 8k/a Amends The Original 8k To File As An Exhibit The Agreement As Described In The Original 8k. Following The Company S Entry Into A Binding, Definitive Agreement Regarding The Line Of Credit, The Company Will File A Copy Of Such Agreement By Amendment To The Original 8k On Form 8k/a Or As An Exhibit With The Next Periodic Report. Except As Expressly Stated Herein And Below, This Form 8k/a Does Not Amend Or Update Any Other Information In The Original 8k, Financial Statements And Exhibits

Show full article

This functionality is available for registred users only

• Full name
  Iovance Biotherapeutics, Inc.
• Registration country
  USA
• Industry
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***